^
Association details:
| Biomarker: | SMO mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
Published date:
11/03/2022
Excerpt:
In the NSCLC discovery cohort, the median progression-free survival in the SMO mutant (SMO_MUT) was longer than that in the wild type (SMO_WT) (23.0 vs. 3.8 months, adjusted p = 0.041).
DOI:
https://doi.org/10.3389/fimmu.2022.955800
